Keyphrases
AKT Pathway
18%
Apoptotic Response
9%
Bcl-xL
9%
Bromodomain
100%
Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit
9%
Enhancer of Zeste Homolog 2 (EZH2)
9%
EphA2
18%
Epigenetic Marks
9%
Epigenetic Mechanisms
9%
Epigenetic Profiling
9%
Epigenetic Switch
9%
Genomic Loci
9%
Genomic Profiling
9%
Group 3 Medulloblastoma
9%
Guided Therapy
9%
H3K27 Acetylation
100%
H3K27ac
18%
H3K27me3
45%
Histone
9%
Improved Outcomes
9%
Medulloblastoma
100%
Medulloblastoma Subgroups
9%
Molecular Pathways
9%
Novel Mechanism
9%
Overall Survival
9%
Overexpression
9%
Pro-survival
9%
Radiation Resistance
27%
Radioresistant
9%
Radiotherapy Resistance
100%
Radiotherapy Response
27%
Relapse Rate
9%
Therapeutic Approaches
9%
Transcriptional Profile
9%
Transcriptional Profiling
9%
Treatment Strategy
9%
Tumor
9%
Vulnerability
100%
Biochemistry, Genetics and Molecular Biology
Bcl-xL
33%
Bromodomain
100%
Enhancer Region
33%
Epigenetic Mechanism
33%
Epigenetics
100%
EZH2
33%
Gene Expression Profiling
33%
Genetics
33%
Genomics
33%
Histone
33%
Overall Survival
33%
Polycomb Repressive Complex 2
33%
Radiosensitivity
100%
Upregulation
66%
Neuroscience
Bromodomain
100%
Cell Signaling
8%
Enhancer Region
8%
Epigenetic Mechanism
8%
Histone
8%
Medulloblastoma
100%
Polycomb Repressive Complex 2
8%
Radiation Therapy
100%
Medicine and Dentistry
Bcl-xL
8%
Cell Signaling Pathway
8%
Enhancer Region
8%
Epigenetic Mechanism
8%
Gene Expression Profiling
8%
Histone
8%
Medulloblastoma
100%
Neoplasm
8%
Overall Survival
8%
Polycomb Repressive Complex 2
8%
Predictive Marker
8%
Radiation Therapy
100%
Radiosensitivity
25%
Recurrence Risk
8%
Upregulation
16%